Navigation Links
Shanghai ChemPartner and ELARA Pharmaceuticals Expand Drug Discovery Collaboration to a New Level
Date:8/4/2009

SHANGHAI, Aug. 4 /PRNewswire-Asia/ -- Shanghai ChemPartner Co., Ltd., (ChemPartner) a wholly owned subsidiary of ShangPharma Corporation, announced today that it has moved its drug discovery collaboration with ELARA Pharmaceuticals to a new level. ChemPartner will provide fully integrated services in the areas of DMPK, pharmacology and toxicology for ELARA's lead oncology programs. Members of the joint project team from both sides will work closely together to design and execute a drug screening cascade.

"This new relationship is a natural result of the high quality services provided by ChemPartner," commented Dr. Joe Lewis, CEO and a founder of ELARA Pharmaceuticals. "The discovery support from ChemPartner helped our Hypoxia Signaling inhibitor program to move from academic discovery stage to early proof of concept. This led to a successful spin off from the European Molecular Biology Laboratory (EMBL) in Heidelberg, Germany. Our new integrated relationship will enable ELARA to further leverage ChemPartner's strong R&D capabilities from discovery to early development phase. We anticipate a stronger strategic partnership down the road as our program progresses."

"We are very pleased to see that our services helped ELARA turn innovative research at a renowned academic institution into a venture funded drug discovery company," said Michael Hui, founder and CEO of ChemPartner. "Our partnership demonstrates the strength of ChemPartner's innovation driven and fully integrated R&D service platform"

About Shanghai ChemPartner

Founded in 2003, Shanghai ChemPartner Company Ltd. (ChemPartner) is one of the leading contract research organizations providing medicinal chemistry, discovery biology, pharmacology, DMPK, toxicology, process R&D, analytical development, formulation and contract manufacturing services to over 80 pharmaceutical and biotech companies in the world. ChemPartner currently has a team of over 1000 scientists including over 80 senior scientific leaders with extensive industry experiences gained from leading global pharmaceutical and biotech companies.

Further information is available at http://www.shangpharma.com .

About ELARA Pharmaceuticals

ELARA Pharmaceuticals is a spin-off of the European Molecular Biology Laboratory in Heidelberg, and was founded to translate basic research findings into novel cancer treatments.

The company is developing a portfolio of highly-potent orally-available inhibitors of the hypoxia signalling pathway. The lead compound shows an excellent in vivo profile and is expected to move into formal preclinical development this year.

Further information is available at http://www.elarapharma.com .


'/>"/>
SOURCE Shanghai ChemPartner Co., Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Shanghai Century Acquisition Corporation Announces Sichuan Kelun Pharmaceutical Co Results for the Six Months Ended June 30, 2007
2. HUYA Bioscience International Licenses Clinical Stage Anti-Arrhythmic Compound from the Shanghai Institute of Materia Medica
3. Cinpathogen Brings Together Over 40 Shanghai Area Hospitals at the First Annual Cinpathogen Hematology Conference
4. Cinpathogen Provides Clinical Diagnostic Consulting Services to Shanghai Area Hospitals
5. Shanghai CRO Service Alliance Adds Clinical Development Capabilities
6. Carna Biosciences Signs Distribution Agreement with Shanghai Universal Biotech Company
7. Cynvec to Present at the 11th Annual Shanghai International Forum on Biotechnology and Pharmaceutical Industry
8. NeoStem Signs Agreement with Shanghai Corporation to Develop A Stem Cell Collection and Treatment Network in Shanghai, Taiwan and Other Targeted China Provinces
9. Sundia and 2 Other CRO Companies Granted Express Customs Clearance Privilege in Shanghai
10. Shanghai ChemPartner and Agios Expand Integrated Drug Discovery Research Collaboration
11. Sundia Shortens CRO Shipment Delivery Time with Express Customs Clearance in Shanghai
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... Rocky Hill, Conn. (PRWEB) , ... April 28, ... ... source of financing and ongoing support for Connecticut's innovative, growing companies, today announced ... early-stage digital health and financial technology (fintech) companies. , “VentureClash looks ...
(Date:4/27/2016)... ... 2016 , ... Cambridge Semantics, the leading provider of Smart Data ... has been named to The Silicon Review’s “20 Fastest Growing Big Data Companies of ... serves the needs of end users facing some of the most complex data challenges ...
(Date:4/27/2016)... , April 27, 2016 ... (CSE: NSK) (OTCPink: NSKQB) ( Frankfurt ... an ihre Pressemitteilung vom 13. August 2015 die ... ihre Finanzen um zusätzliche 200.000.000 Einheiten auf 400.000.000 ... Dollar zu bringen. Davon wurden 157.900.000 Einheiten mit ...
(Date:4/27/2016)... ... April 27, 2016 , ... PathSensors, Inc., a leading environmental ... Lamka will assist PathSensors in expanding the use of the company’s CANARY® technology ... test platform for the detection of harmful pathogens, including a number of bacteria, ...
Breaking Biology Technology:
(Date:4/15/2016)... CHICAGO , April 15, 2016  A ... companies make more accurate underwriting decisions in a ... offering timely, competitively priced and high-value life insurance ... health screenings. With Force Diagnostics, rapid ... and lifestyle data readings (blood pressure, weight, pulse, ...
(Date:3/31/2016)... Florida , March 31, 2016 ... ) ("LegacyXChange" or the "Company") LegacyXChange ... potential users of its soon to be launched online ... ( https://www.youtube.com/channel/UCyTLBzmZogV1y2D6bDkBX5g ) will also provide potential ... use of DNA technology to an industry that is ...
(Date:3/22/2016)... 2016 According to ... for Consumer Industry by Type (Image, Motion, Pressure, ... & IT, Entertainment, Home Appliances, & Wearable ... 2022", published by MarketsandMarkets, the market for ... USD 26.76 Billion by 2022, at a ...
Breaking Biology News(10 mins):